Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
Intelligent Bio Solutions completed all cybersecurity and software review items for its upcoming FDA 510(k) submission, resolving 100% of medium-risk vulnerabilities and 19 SBOM issues. The company remains on track to submit its 510(k) notification in the second half of 2026, targeting codeine detection as the initial indication.
Key figures
- Drug Name
- Intelligent Fingerprinting Drug Screening System
- Initial indication
- codeine detection
- Submission timeline
- calendar H2 2026
- Production cost savings
- >40%
- Gross margin improvement
- ~20 percentage points
- Sbom vulnerabilities resolved
- 19
- Low risk vulnerabilities remaining
- 2
- Medium risk vulnerabilities remediated
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.